Do GLP-1 receptor agonists increase the risk of retinopathy in type 2 diabetes?

Diabetic retinopathy is eye damage caused by high blood sugar damaging the small blood vessels in the retina. It is a common complication of type 2 diabetes. The question is whether GLP-1 receptor agonists, a class of diabetes and weight drugs, make this eye problem more likely. The short answer: the evidence is mixed. Some analyses find a small increase in early-stage retinopathy, but the risk seems to vary by drug and may be tied to how fast blood sugar falls rather than the drug itself.

What the research says

A 2023 meta-analysis of 93 randomized clinical trials looked specifically at GLP-1 receptor agonists and diabetic retinopathy. It found that GLP-1 receptor agonist use was linked to a higher risk of early-stage retinopathy compared to placebo (risk ratio 1.31) and more early-stage retinal adverse events (risk ratio 1.29) ¹¹. However, compared to insulin, these drugs appeared to protect against late-stage retinopathy (risk ratio 0.38) ¹¹. The analysis also found that one specific drug, albiglutide, drove much of the early-stage signal, while other GLP-1 receptor agonists did not show the same pattern ¹¹. This suggests the effect may not be a class-wide problem.

A separate 2021 meta-analysis of cardiovascular and kidney outcome trials in people with type 2 diabetes also examined retinopathy as a safety outcome. That analysis included major trials such as AMPLITUDE-O and looked at retinopathy alongside other safety concerns like pancreatitis and severe hypoglycemia ⁹. The results from that broader safety analysis did not show a clear, consistent increase in retinopathy risk across the GLP-1 receptor agonist class ⁹.

Other research on type 2 diabetes complications describes retinopathy as one of the key microvascular problems that doctors monitor for in all patients with diabetes, regardless of which drugs they take ¹⁰. A 2025 review of type 2 diabetes mechanisms and treatments notes that GLP-1 receptor agonists offer solid blood sugar control, weight control, and reduced cardiovascular risk, and that managing complications like retinopathy requires early diagnosis and comprehensive care ¹⁰. That review does not flag retinopathy as a specific harm of GLP-1 receptor agonists.

One proposed explanation for the early-retinopathy signal is that rapid improvement in blood sugar can temporarily worsen retinopathy, a phenomenon sometimes seen when diabetes control improves quickly. The 2023 meta-analysis found demographic differences between groups, including HbA1c and diabetes duration, which could confound the results ¹¹. More research is needed to separate the drug effect from the effect of rapid glucose lowering.

What to ask your doctor

• Ask whether your current diabetes medications, including any GLP-1 receptor agonist, affect your eye screening schedule.
• Ask how often you should have a dilated eye exam, especially if you have had diabetes for many years or have existing eye changes.
• Ask whether rapid improvements in blood sugar could affect your eyes and what signs to watch for.
• Ask whether the specific GLP-1 receptor agonist you take has been studied for retinopathy risk.
• Ask about your overall retinopathy risk factors, including blood pressure, blood sugar control, and how long you have had diabetes.